Literature DB >> 3596812

[Lipoid A antibody titer in the human].

W Marget.   

Abstract

Lipid A is the toxic component of endotoxin in gram-negative bacteria. Antibodies to lipid A are not usually found in healthy persons (or only at a low titer) without a corresponding history of infection. Even gram-negative septicemia is found to be accompanied by only low titers. A completely different situation is seen in patients with chronic or recurrent infections due to Enterobacteriaceae and other gram-negative bacteria. Here it is notable that the antibody titer varies with the type of disorder (e.g. cystitis and pyelonephritis). A severe wound infection, e.g. due to Pseudomonas aeruginosa, also leads to measurable lipid A antibody titers. Varying antibody titers can be observed in cystic fibrosis, Crohn's disease, and severe surgical infections. One can conclude that a significantly elevated antibody titer develops during an extensive tissue involvement of long duration and indeed is caused by tissue inhibition by endotoxin. Based on clinical experience, it can be assumed that lipid A antibodies present in the body have a protective effect in septic shock.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3596812     DOI: 10.1007/bf01650220

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  [Lipid A antibody titers in pyelonephritis and other gram-negative infections (author's transl)].

Authors:  G Simon; B Reindke; W Marget
Journal:  Infection       Date:  1974       Impact factor: 3.553

2.  Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1971-12-22

3.  [Lipid A antibody titers and O antibody titers in Crohn's disease, ulcerative colitis and acute enteritis (author's transl)].

Authors:  P Schüssler; W Kruis; W Marget
Journal:  Med Klin       Date:  1976-10-29

4.  Relevance of vesico-ureteric reflux in development of lipid A antibodies in recurrent urinary tract infections in children--a preliminary study.

Authors:  P J Mar; W Marget; K Schneider; B H Belohradsky; R Roos
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

5.  Lipid A antibody determinations using ELISA on patients at a children's hospital: a preliminary report.

Authors:  W Marget; M Weiss; B Ruhland
Journal:  Infection       Date:  1983 Mar-Apr       Impact factor: 3.553

6.  Preliminary study on administration of high-titer lipid A antibody serum in sepsis and septic shock patients.

Authors:  W Marget; P J Mar; L Jaspers; K Possinger; H Haslberger
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

  6 in total
  3 in total

1.  ELISA for antibodies to lipid A, lipopolysaccharides and other hydrophobic antigens.

Authors:  M A Freudenberg; A Fomsgaard; I Mitov; C Galanos
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

2.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

3.  Endotoxin neutralization as a biomonitor for inflammatory bowel disease.

Authors:  Keith Champion; Laura Chiu; John Ferbas; Michael Pepe
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.